Venn Life Sciences has posted a wider H1 loss for the year of €0.7m, from a loss of €0.3m. Revenue was €9.1m, from €4.3m.
"The future divestment of Innovenn will have a positive impact on the Company's financial performance in the second half of this year," said non-executive chair Allan Wood.
"Importantly the disposal of this business, once achieved, will enable management to singularly focus on the growth of our core business.
"The addition of Kinesis into the Company has been well received by the market and we expect the second half of the year to see the benefits of this acquisition. Overall we continue to see opportunities for further growth, both organically and through M&A."